VET3-TGI, a TGF-Beta Targeting Clinical Oncolytic Virus Developed from the VET Platform for Systemic Delivery
Time: 10:00 am
day: Day Two
Details:
- KaliVir has developed the VET platform to develop oncolytic virus backbones capable of achieving systemic delivery to solid tumors
- VET3-TGI represents the lead internal product from this platform and is undergoing clinical translational development
- In addition to unique intravenous delivery capabilities, VET3-TGI targets TGF-beta within the tumor microenvironment
- Pre-clinical data with this OV have demonstrated mechanisms resulting in multiple complete responses after systemic delivery in multiple mouse tumor models, even in the face of pre-existing anti-viral immunity
